U.S. regulators approved Kisunla last July for mild or early cases of dementia caused by the fatal, mind-robbing disease. That came a year after they approved a similar drug, Leqembi, from Japanese ...

The partners’ Kisunla-rivaling Leqembi eventually won CHMP’s favor in February, albeit in a restricted patient population of those with mild Alzheimer’s-related cognitive impairment or ...

Kisunla has already been approved in other countries like Japan and China. It was also approved by U.S. regulators last July, a year after another similar drug called Leqembi from Japanese ...

(Bloomberg) -- Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal ...

EU rejection based on risk of serious brain swelling Lilly seeks re-examination of EU decision on Kisunla CHMP previously rejected Leqembi before recommending approval March 28 (Reuters ...

U.S. regulators approved Kisunla last July for mild or early cases of dementia caused by the fatal, mind-robbing disease. That came a year after they approved a similar drug, Leqembi, from ...

U.S. regulators approved Kisunla last July for mild or early cases of dementia caused by the fatal, mind-robbing disease. That came a year after they approved a similar drug, Leqembi, from ...